trending Market Intelligence /marketintelligence/en/news-insights/trending/_lp7juji28m7LrNR84WjpA2 content esgSubNav
In This List

Hemogenyx Pharmaceuticals director to resign

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Hemogenyx Pharmaceuticals director to resign

Hemogenyx Pharmaceuticals Plc said Robin Campbell would resign as a nonexecutive director, effective Jan. 5, 2019.

London-based Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company that focuses on the discovery, development and commercialization of novel therapies and treatments for blood diseases.